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We examined the role of vascular function and inﬂammation in the
development and failure to heal diabetic foot ulcers (DFUs). We
followed 104 diabetic patients for a period of 18.4 6 10.8 months.
At the beginning of the study, we evaluated vascular reactivity
and serum inﬂammatory cytokines and growth factors. DFUs
developed in 30 (29%) patients. DFU patients had more severe
neuropathy, higher white blood cell count, and lower endothelium-
dependent and -independent vasodilation in the macrocirculation.
Complete ulcer healing was achieved in 16 (53%) patients, whereas
13 (47%) patients did not heal. There were no differences in the
above parameters between the two groups, but patients whose
ulcers failed to heal had higher tumor necrosis factor-a, monocyte
chemoattractant protein-1, matrix metallopeptidase 9 (MMP-9),
and ﬁbroblast growth factor 2 serum levels when compared with
those who healed. Skin biopsy analysis showed that compared with
control subjects, diabetic patients had increased immune cell in-
ﬁltration, expression of MMP-9, and protein tyrosine phosphatase-
1B (PTP1B), which negatively regulates the signaling of insulin,
leptin, and growth factors. We conclude that increased inﬂamma-
tion, expression of MMP-9, PTP1B, and aberrant growth factor
levels are the main factors associated with failure to heal DFUs.
Targeting these factors may prove helpful in the management
of DFUs. Diabetes 61:2937–2947, 2012
D
iabetic foot ulcers (DFUs) are one of the most
common and serious complications of diabetes
and affects 15% of all diabetic patients, leading
to .80,000 amputations per year in the U.S.
and results in a high ﬁnancial burden (1,2). Neuropathy, pe-
ripheral vascular disease, and reduced resistance to infection
are recognized risk factors leading to the development of
DFUs, which have all the characteristics of a chronic wound
(3,4).
In the current study, we have well characterized and pro-
spectively followed-up a large number of diabetic patients,
the majority of whom were at risk for developing foot
ulceration. Our main hypothesis was that changes in the
peripheral nerve function and the diabetes-associated
proinﬂammatory state are related not only to the
development of DFUs but also to wound-healing failure.
RESEARCH DESIGN AND METHODS
We enrolled 108 diabetic patients and 36 healthy control subjects. The diabetic
subjects were divided into those at low risk for developing foot ulceration and
those at high risk, according to their neuropathic status (5). The exclusion
criteria were presence of foot ulceration at the time of recruitment, clinically
present peripheral arterial disease, end-stage renal disease (patients on renal
dialysis or kidney transplantation), and any other serious chronic disease that
can affect wound healing. For the comparison between diabetic patients with
and without foot ulceration, we used a group of seven diabetic patients with
active foot ulceration (6 male subjects, aged 55 6 11 years). The protocol was
approved by the institutional review board of the Beth Israel Deaconess Medical
Center. All participants gave written informed consent.
Baseline visit. All subjects attended the Joslin-Beth Israel Deaconess Foot
Center and the General Clinical Research Center where they had a full physical
examination and all tests described below. All diabetic patients received edu-
cation about foot care and were seen regularly by their podiatrist as required.
Exitvisit.Alldiabeticpatientswereaskedtoreturnforafollow-upvisitat~18–24
months, whereas the healthy control subjects only were seen during the base-
line visit. The same types of tests that were performed during the baseline also
were performed at the exit visit.
DFU development and treatment. Participants were asked to contact the
study coordinator in case of the development of foot ulceration or any other
adverse event. In addition, they were contacted over regular periods of time by
the study coordinator. Treatment for any ulceration that occurred during the
study was providedat the Joslin-Beth Israel Deaconess Foot Center accordingto
standard guidelines (4). The cause of the foot ulceration and its progression
were recorded.
Clinical and laboratory assessments. Serum was analyzed for the mea-
surements of inﬂammatory cytokines, growth factors, and biochemical markers
of endothelial function using a Luminex 200 apparatus (Luminex, Austin, TX)
and Millipore multiplex immunoassay panels (Millipore, Chicago, IL).
Evaluation of diabetic neuropathy and peripheral vascular disease. The
symptoms were evaluated by using the Neuropathy Symptom Score (NSS) and
the clinical signs by using the Neuropathy Disability Score (NDS) and the as-
sessment of vibration perception threshold (VPT) and cutaneous perception
threshold using a set of 12 Semmes-Weinstein monoﬁlaments ranging from 2.83
to10.0g.PatientswhoweredeﬁnedathighriskoffootulcerationhadanNDS$5
and were unable to feel a 5.07 Semmes-Weinstein monoﬁlament (5). Detailed
description of these standard tests has been provided elsewhere (5).
Vascular reactivity tests. All measurementswereperformedwiththe subjects
in the fasting state. The vascular reactivity of the forearm-skin microcirculation
was evaluated by laser Doppler perfusion imaging measurements before and
after the iontophoresis of acetylcholine chloride (Ach; endothelium-dependent
vasodilation) and sodium nitroprusside (SNP; endothelium-independent vaso-
dilation),as previously described (6).The nerveaxon reﬂex–related vasodilation
(NARV) was performed by using a single-point laser probe and the Moor DRT4
System (6). The ﬂow-mediated brachial artery dilation (FMD; endothelium de-
pendent) and nitroglycerine-induced dilation (NID; endothelium independent)
were measured in accordance with published guidelines (7).
Evaluation of oxy- and deoxyhemoglobin. Data were collected using the
HyperMed System (HyperMed, Burlington, MA), as previously described (8).
Skin biopsies
Forearm-skin biopsies. One 2-mm skin-punch biopsy was taken from the
volar aspect of the forearm.
Foot-skin biopsies. Discarded skin specimens were obtained from subjects
who underwent foot surgery for various reasons. The biopsy staining was
performed under the supervision of a trained pathologist with experience in
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ORIGINAL ARTICLEdermatopathology (A.K.) using standard techniques. To evaluate the percentage
of cells expressing factor XIIIa and matrix metallopeptidase-9 (MMP-9), a score
of 1 was entered when 1–5 of the cells were expressing the antibody, a score of 2
for 5–10 of the cells, and a score of 3 for .10 of the cells. For protein tyrosine
phosphatase-1B (PTP1B), a score of 1 was entered for 1–5c e l l s ,2f o r5 –10 cells,
3f o r1 0 –20 cells, and 4 for .20 positive cells. The intensity of each antibody
expression was scored as follows: 1 for weak, 2 for moderate, and 3 for strong
expressions for all utilized antibodies. Western blot analysis was performed
using standard techniques, and protein quantiﬁcation was normalized with
tubulin.
Statistical analysis. Data analysis was performed in collaboration with a
biostatistician(C.G.)usingMinitab(Minitab,StateCollege,PA).Theanalysiswas
undertaken by univariate techniques and modeling the data through multiple
logistic regression. ANOVA was used for normally distributed data. Nonpara-
metrical data were analyzed through Kruskal-Wallis ANOVA. The comparison
between baseline and exit-visit measurements was made by using the paired
t test for parametrically distributed data and the Wilcoxon signed rank test for
nonnormal data. A logistic regression model was run having as an outcome
variable the development of DFUs, whereas the NDS (low = NDS #5, high =
NDS .5), forearm and dorsum of the foot NARV, and FMD were used as ex-
planatory variables. The model was ﬁtted to data after controlling for the age
and sex of the study participants.
RESULTS
The demographics of the patients at low and high risk for
DFUs and the control subjects are presented in Table 1.
Four (4%) diabetic patients withdrew consent or were lost
to follow-up and were excluded from the study. Twenty-
four diabetic patients were characterized as being at low
risk for developing foot ulceration and 80 as being at high
risk. As expected, diabetic patients at high risk had different
measurements of nerve function (NSS, NDS, VPT, and
Semmes-Weinstein monoﬁlaments). Furthermore, FMD
and NID and foot-skin endothelium-dependent vasodila-
tion were reduced in both diabetic groups, whereas the
foot-skin SNP response and the NARV response at both
the forearm and dorsum of the foot were reduced in the
diabetic patients at high risk. The differences in the se-
rum cytokines and growth factors in the three groups are
shown in Table 2. In general, diabetic patients at high risk
had higher levels of inﬂammatory cytokines.
DFU development and healing. The mean follow-up time
was (means 6 SD) 18.4 6 10.8 months. DFUs developed in
30 (29%) diabetic patients. The average period of time be-
tween enrollment in the study and the development of the
ﬁrst foot ulceration was 8.0 6 7.1 months (Fig. 1). All sub-
jects who developed ulceration belonged to the high-risk
group, resulting in an annual rate of 24% in this group. The
results of logistic regression analysis identifying the risk
factors for the development of DFUs are shown in Sup-
plementary Table 1. In short, high NDS (.5) was the most
important predictor, whereas age, forearm NARV, and FMD
also were associated with the risk of DFUs.
Complete wound healing during the ﬁrst 12 weeks after
ulceration occurred in 16 (53%) patients, whereas the
remaining 14 (47%) went on to develop chronic, nonhealed
foot ulcers. The differences in the clinical characteristics
between the diabetic patients who did not develop foot
ulcers and those who did are shown in Table 3. Table 3 also
contains the comparisons between the patients who had
complete ulcer healing versus those who did not heal.
Patients who developed DFUs had more severe neuropathy,
as seen by the NDS, VPT, and Semmes-Weinstein mono-
ﬁlament measurements; higher creatinine and white blood
cell count; and lower FMD and NID than those who did not.
No differences were observed in any of the above mea-
surements between the patients whose ulcers healed when
compared with those whose ulcers did not.
The differences in growth factors and cytokines between
the patients who did not develop DFUs and those who did
are shown in Table 4. The most notable differences included
a reduction in epidermal growth factor (EGF), ﬁbroblast
growth factor (FGF), g-interferon (IFN-g), macrophage in-
ﬂammatory protein 1 a (MIP-1a), and MIP-1b and a marginal
reduction in interleukin (IL)-6 serum levels at baseline in the
patients who developed DFUs when compared with those
who did not. The differences between the patients whose
ulcers healed and those whose ulcers did not also are shown
in Table 4. The main differences included an increase in the
platelet-derived growth factor (PDGF)-AA, FGF, leptin, gran-
ulocyte colony-stimulating factor (G-CSF), GRO, monocyte
chemoattractant protein 1 (MCP-1), MMP-9, and tissue plas-
minogen activator-1 (tPAI-1) serum levels in the patients
whose ulcers failed to heal (Fig. 2).
The growth factor and cytokine levels of patients with
healed and nonhealed ulcers also were compared with
a group of diabetic patients who had an active foot ulcer
when blood tests were performed, and the results are shown
in Supplementary Table 2. Of interest, when compared with
patients whose ulcers healed, patients whose ulcers failed to
heal had measurements in most cytokines, including PDGF-AA,
FGF, transforming growth factor (TGF) a, GRO, and MMP-9,
that were closer to the group with the active ulcers.
Skin biopsy analysis
Forearm-skin biopsies. Eighty-three subjects (12 healthy
control subjects and 71 diabetic patients) underwent
forearm-skin biopsy. The diabetic patients were subdivided
to 12 low-risk and 59 high-risk diabetic patients. The high-
risk group included 10 subjects who developed a foot ulcer
that healed and 13 who developed a chronic wound. There
were no major differences between the subjects who un-
derwent a skin biopsy and those who did not. Because there
were no major differences among the various diabetic
groups, the main comparisons were made between the
control and diabetic group and are presented in Table 5.
The results of the diabetic patients who did not develop
DFUs, those who developed DFUs, and the two subgroups
w h o s eD F U sh e a l e do rf a i l e dt oh e a la r es h o w ni nt h e
Supplementary Table 3.
Hematoxylin and eosin analysis. The total number of
cells per biopsy in the dermis of the forearm-skin biopsies
was higher in the diabetic patients when compared with
the control subjects (Table 5). The number of inﬂammatory
cells around vessels, a strong indication of inﬂammation,
also was increased in diabetic patients (Fig. 3A and B). The
number of blood vessels was higher in the patients who
developed an ulcer that healed compared with those whose
ulcer failed to heal.
Markers of inﬂammatory cells. The percentage of cells
expressing factor XIIIa, a marker of dermal dendrocytes,
and the intensity of staining were higher in diabetic patients.
The number of CD45RO-expressing cells around blood
vessels, a marker of lymphocytes, also was higher in diabetic
patients (Fig. 3C and D).
CD31 staining. The number of CD31 (endothelial) pro-
liferating cells around preexisting vessels, the number of
CD31-positive cells in the dermis, and the number of blood
vessels, including single-positive CD31 cells, was higher in
diabetic patients.
MMP-9 staining. The antibody was expressed at the
basement membrane of the blood vessels by endothelial
cells, ﬁbroblasts/ﬁbrocytes, and inﬂammatory cells. The
number of stromal cells expressing the antibody was higher
in diabetic patients (Fig. 3E and F).
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Clinical characteristics of the three studied groups
Control
subjects
Low-risk
diabetic patients
High-risk
diabetic patients P
n 36 24 80 NS
Age (years) 58 6 75 7 6 95 7 6 8N S
Males (%) 18 (50) 10 (42) 56 (70) ,0.05 (control and
low-risk subjects vs.
high-risk subjects
Diabetes type (1/2) — 10/14 42/64 NS
Diabetes duration (years) — 12 6 12 21 6 14 ,0.01 (low-risk subjects vs.
high-risk subjects)
BMI (kg/m
2) 27.6 6 8.0 34.5 6 7.6 33.1 6 7.1 ,0.0001 (control subjects vs.
low- and high-risk subjects)
Systolic blood pressure (mmHg) 127 6 22 134 6 19 147 6 19 ,0.0001 (control and
low-risk subjects vs.
high-risk subjects)
Diastolic blood pressure (mmHg) 73 6 11 76 6 10 76 6 10 NS
Heart rate (bpm) 65 6 87 4 6 15 76 6 11 ,0.0001 (control subjects vs.
low- and high-risk subjects)
HbA1c (%) 5.6 6 0.3 7.5 6 1.4 8.2 6 1.9 ,0.0001 (control subjects vs.
low- and high-risk subjects)
Creatinine (mg/dL) 0.9 6 0.2 0.8 6 3 1.2 6 0.6 ,0.001 (control and
low-risk subjects vs.
high-risk subjects)
Estimated glomerular ﬁltration rate
(mL/min/1.73 m
2)8 3 6 13 100 6 46 71 6 25
,0.0001 (low-risk subjects vs.
control and high-risk subjects)
White blood cell count 6,025 6 1,751 6,233 6 1,871 7,407 6 1,743 ,0.01 (control and
low-risk subjects vs.
high-risk subjects)
Total cholesterol (mg/dL) 201 6 30 168 6 38 178 6 38 = 0.001 (control subjects vs.
low- and high-risk subjects)
HDL cholesterol 60 6 20 52 6 18 50 6 14 ,0.02 (control subjects vs.
high-risk subjects)
NSS 0 6 13 6 35 6 3 ,0.0001 (control subjects vs.
low- and high-risk subjects;
low-risk subjects vs.
high-risk subjects)
NDS 0 6 12 6 11 2 6 7 ,0.0001 (control and
low-risk subjects vs.
high-risk subjects)
VPT (V) 8 6 41 3 6 53 5 6 15 ,0.0001 (control and
low-risk subjects vs.
high-risk subjects)
Semmes-Weinstein monoﬁlaments 3.90 6 0.48 4.18 6 0.44 5.95 6 0.91 ,0.0001 (control and
low-risk subjects vs.
high-risk subjects)
Ankle-brachial index 1.1 6 0.1 1.1 6 0.1 1.1 6 0.2 NS
FMD (%) 8.6 6 2.2 5.9 6 1.0 5.2 6 2.0 ,0.0001 (control subjects vs.
low- and high-risk subjects)
NID (%) 17.4 6 2.9 14.4 6 2.2 12.4 6 4.9 ,0.0001 (control subjects vs.
low- and high-risk subjects)
Forearm NARV (%) 260 (150–518) 207 (52–290) 136 (40–248) ,0.01 (control subjects vs.
high-risk subjects)
Foot endothelium-dependent vasodilation
(Ach response) (%) 28 (14–50) 19 (9–28) 15 (8–26)
,0.02 (control subjects vs.
low- and high-risk subjects)
Foot endothelium-independent vasodilation
(SNP response) (%) 25 (16–50) 22 (13–32) 17 (9–30)
,0.02 (control subjects vs.
high-risk subjects)
Foot NARV (%) 49 (14–108) 33 (9–61) 18 (34–48) ,0.01 (control subjects vs.
high-risk subjects)
Forearm oxyhemoglobin 27 6 93 0 6 11 29 6 13 NS
Forearm deoxyhemoglobin 32 6 93 1 6 83 2 6 9N S
Foot oxyhemoglobin 30 6 16 32 6 13 29 6 13 NS
Foot deoxyhemoglobin 40 6 17 29 6 10 32 6 11 ,0.01 (control subjects vs.
low- and high-risk subjects)
Data are means 6 SD, medians (ﬁrst to third quartiles), or n (%). NS, not signiﬁcant.
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basal layer of the epidermis where mitotically active cells
exist, the dermis cells (ﬁbrocytes or ﬁbroblasts), the endo-
thelial cells of blood vessels, and the inﬂammatory cells. The
staining pattern was mainly membranous or paranuclear dot
like. When compared with healthy control subjects, PTP1B
was expressed by a higher number of epidermal basal cells,
endothelial cells, ﬁbrocytes and/or ﬁbroblasts, and inﬂam-
matory cells in diabetic patients (Fig. 3G and H). The intensity
of staining in all cells also was higher in diabetic patients.
The number of endothelial cells expressing the antibody
was marginally higher in the diabetic patients who de-
veloped and failed to heal their ulcer when compared with
the subjects whose ulcer had healed (Supplementary Table 3).
There were no differences between type 1 and type 2 diabetic
patients.
Vascular endothelial growth factor staining. No dif-
ferences were observed in the number of epidermal basal
cells, endothelial cells, ﬁbrocytes, and/or ﬁbroblasts that
expressed the antibody.
Foot-skin biopsies
Immunohistochemistry. Immunohistochemistry was per-
formed in dorsal foot discarded-skin specimens that were
obtained during foot surgery from 8 nondiabetic healthy
control subjects (aged 58 6 18, 3 male subjects) and 7 di-
abetic patients (aged 58 6 16, 5 male subjects). The results
were similar to the ones observed in the forearm biopsies,
although they failed to reach statistical signiﬁcance in most
cases because of the small number of participants. Thus,
hematoxylin and eosin analysis showed that the total num-
ber of cells per biopsy in the dermis tended to be higher
in diabetic patients (196 6 78 vs. 107 6 23, P =0 . 1 0 ) .T h e
number of inﬂammatory cells around vessels also tended to
be higher in diabetic patients (62 6 39 vs. 43 6 32, P =N S ) .
MMP-9 expression by inﬂammatory cells also tended to be
higher (2.2 6 0.8 vs. 1.8 6 0.4, P = NS). PTP1B expression by
TABLE 2
Growth factor and cytokine results
Control
subjects
Low-risk
diabetic patients
High-risk
diabetic patients P
PDGF-AA (ng/mL) 25.5 (19.6–32.9) 24.2 (14.9–33.1) 16.7 (11.1–29.2) ,0.02 (control subjects vs.
high-risk subjects)
EGF (pg/mL) 29.4 (20.3–73.7) 55.3 (45.8–97.6) 36.9 (23.7–51.6) ,0.02 (low-risk subjects vs.
control and high-risk subjects)
FGF-2 (pg/mL) 36.9 (32.3–74.0) 42.1 (27.6–64.2) 36.2 (27.5–46.8) ,0.05 (control vs. high-risk
subjects)
TGFa (pg/mL) 13.2 (8.4–34.8) 11.3 (8.2–23.4) 14.5 (9.8–30.50) NS
VEGF (pg/mL) 112 (44–251) 179 (37–458) 145 (67–254) NS
Insulin (pg/mL) 345 (176–515) 514 (385–1,050) 729 (371–1,130) ,0.01 (control subjects vs.
low- and high-risk subjects)
Leptin (ng/mL) 6.7 (2.0–11.8) 20.2 (9.6–37.2) 16.3 (7.3–26.8) ,0.0001 (control subjects vs.
low- and high-risk subjects)
G-CSF (pg/mL) 11.6 (8.4–21.9) 25.5 (12.5–31.2) 19.4 (13.9–25.2) ,0.02 (control subjects vs.
low- and high-risk subjects)
IL-6 (pg/mL) 10.4 (7.2–14) 15.3 (7.3–30.7) 14.6 (10.1–34.7) ,0.005 (control subjects vs.
high-risk subjects)
IL-8 (pg/mL) 10.1 (6.4–25.1) 17.2 (10.0–67.3) 18.9 (10.7–36.0) ,0.05 (control subjects vs.
low-risk subjects)
IFN-g (pg/mL) 6.3 (5.4–10.8) 14.4 (8.9–25.2) 9.5 (3.7–18.3) NS
MCP-1 (pg/mL) 535 (393–739) 436 (260–631) 526 (392–713) NS
MIP-1a (pg/mL) 49.9 (19.1–91.9) 57.6 (38.1–79.7) 50.6 (36.4–67.4) NS
MIP-1b (pg/mL) 54.1 (38.3–72.7) 67.8 (63.5–114.8) 55.9 (36.7–79.6) NS
IL-2 receptor serum (pg/mL) 59.2 (23.5–106) 84.4 (29.7–105.5) 64.5 (33.1–99.6) NS
MMP-9 (ng/mL) 237 (167–356) 181 (127–305) 220 (151–329) NS
TNFa (pg/mL) 5.17 (3.94–7.04) 6.69 (4.61–8.77) 6.90 (5.16–9.05) ,0.01 (control subjects vs.
high-risk subjects)
sE-selectin (ng/mL) 19.6 (13.5–33.1) 23.7 (15.1–44.5) 32.4 (19.2–49.9) ,0.001 (control subjects vs.
high-risk subjects)
Soluble intracellular adhesion
molecule-1 (ng/mL) 89.7 (68.8–129.8) 101 (62.8–147.5) 134.0 (94.0–178.8) ,0.02 (control and low-risk
subjects vs. high-risk subjects)
Soluble vascular cell adhesion
molecule-1 (ng/mL) 854 (641–1073) 873 (479–1,073) 998 (732–1,198) = 0.054 (low-risk subjects vs.
high-risk subjects)
tPAI-1 (ng/mL) 47 (33–58) 64 (38–73) 49 (38–74) NS
High-sensitivity C-reactive protein
(mg/mL) 3.97 (1.88–6.84) 6.13 (1.51–37.13) 13.60 (4.80–47.80) ,0.0001 (control subjects vs.
high-risk subjects)
Fibrinogen (ng/mL) 308 (191–633) 345 (182–1,040) 770 (445–1,205) ,0.05 (control and low-risk
subjects vs. high-risk subjects)
Data are medians (ﬁrst to third quartiles). NS, not signiﬁcant.
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higher (2.7 6 0.6 vs. 2.0 6 0.2, P =N S ) .
Western blot analysis. We also measured the protein
expression using Western blot analysis in foot-skin specimens
from 11 healthy control subjects (aged 55 6 18 years,
4 male subjects) and 9 diabetic patients (aged 62 6 13,
6 male subjects) as described in the Supplemental Data.
The majority of these subjects were similar with the ones
above because, when feasible, specimens were tested for both
immunohistochemistry and Western blot analysis. Protein
expression was higher in diabetic patients than the control
subjects regarding MMP-9 (140 6 52 vs. 100 6 35, P =
0.053), PTP1B (149 6 72 vs. 100 6 21, P , 0.05), and
vascular endothelial growth factor (VEGF) (156 6 72 vs.
FIG. 1. Cumulative incidence of DFUs.
TABLE 3
Clinical characteristics of diabetic patients with and without foot ulceration
Diabetic patients
with no ulcers
Diabetic patients
with ulcers P Healed ulcers
Nonhealed
ulcers P
n 74 30 16 14
Age (years) 58 6 85 5 6 8N S 5 7 6 85 3 6 8N S
Diabetes duration (years) 19 6 15 19 6 11 NS 20 6 10 19 6 11 NS
HbA1c (%) 8.0 6 1.9 8.2 6 1.7 NS 7.9 6 1.5 8.5 6 2.0 NS
NDS 8 6 71 5 6 6 0.0001 15 6 51 4 6 7N S
VPT (V) 27 6 16 39 6 14 ,0.01 40 6 13 37 6 15 NS
Semmes-Weinstein monoﬁlaments 5.14 6 1.09 6.45 6 0.48 ,0.001 6.33 6 0.59 6.64 6 0.07 NS
Ankle-brachial index 1.1 6 0.2 1.1 6 0.2 NS 1.2 6 0.2 1.1 6 0.2 NS
Creatinine (mg/dL) 1.00 6 0.47 1.27 6 0.67 ,0.05 1.09 6 0.31 1.48 6 0.91 NS
Estimated glomerular ﬁltration
rate (mL/min/1.73 m
2)8 1 6 34 69 6 27 NS 76 6 25 61 6 27 NS
White blood cell count 6,892 6 1,804 7,697 6 1,817 ,0.05 7,231 6 1,552 8,269 6 2,012 NS
FMD (%) 5.6 6 1.9 4.6 6 1.94 ,0.02 4.6 6 1.7 4.7 6 1.2 NS
NID (%) 13.8 6 4.9 10.6 6 2.6 ,0.01 10.9 6 2.7 10.3 6 2.5 NS
Forearm NARV (%) 181 (67–289) 91 (21–186) ,0.05 134 (24–194) 68 (11–186) NS
Foot endothelium-dependent
vasodilation (Ach response) (%) 13 (7–23) 17 (8–32) NS 16 (9–29) 20 (7–34) NS
Foot endothelium-independent
vasodilation (SNP response) (%) 19 (9–30) 21 (9–35) NS 23 (11–38) 16 (6–29) NS
Foot NARV (%) 26 (8–50) 13 (0–51) NS 13 (5–70) 13 (0–46) NS
Forearm oxyhemoglobin 31 6 13 27 6 10 NS 27 6 13 26 6 7N S
Forearm deoxyhemoglobin 32 6 83 2 6 11 NS 32 6 93 3 6 13 NS
Data are means 6 SD or medians (ﬁrst to third quartiles). NS, not signiﬁcant.
T. DINH AND ASSOCIATES
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in PDGF-BB (122 6 49 vs. 100 6 29, P = NS) (Supple-
mentary Fig. 1).
Second visit. Fifty-eight diabetic patients (including 17
patients who developed a foot ulcer during the study)
returned for a second (exit) visit 20 6 8 months after the
ﬁrst visit. There were no major differences in any of the
clinical characteristics between the patients who returned
for a second visit and those who did not. The differences
between baseline and exit visit in all 59 patients, the sub-
group of the 41 patients who did not develop a foot ulcer,
and the 17 patients who developed foot ulceration are
shown in Supplementary Table 4 (clinical characteristics)
and Supplementary Table 5 (growth factors and cyto-
kines). No differences were observed in the analysis of
biopsies that were taken in visits 1 and 2 (data not
shown).
DISCUSSION
The main ﬁndings of the present prospective cohort study
are that although neuropathy and vascular factors are as-
sociated with the development of DFUs, the main factors
that are associated with failure to heal these ulcers are
preexisting increased serum levels of inﬂammatory cyto-
kines, MMP-9, and various growth factors. At the skin level,
diabetes was associated with inﬂammation and increased
expression of MMP-9 and PTP1B, factors that are associ-
ated with inﬂammation, can lead to resistance of the growth
factor action, and may be responsible for the observed
raised levels in the patients whose ulcers failed to heal.
As would be expected, only neuropathic patients de-
veloped DFUs at a rate that was similar to the one predicted
by previous prospective studies, indicating that the selected
subjects were representative of the general diabetic pop-
ulation (5,9). It also is of interest that the forearm NARV
was a risk factor, indicating the existence of more severe
peripheral neuropathy that affected the c-nociceptive ﬁbers
of the upper extremity in the DFU group. In addition, both
endothelium-dependent and -independent vasodilation in
the macrocirculation were reduced in the patients who
developed DFUs, indicating that the same vascular factors
that are associated with excess cardiovascular mortality in
diabetes also are involved in foot ulceration (10).
A major novel observation of this study is that although
none of the above factors was associated with complete
wound healing, the main factors involved were inﬂamma-
tory cytokines and growth factors. Thus, failure of an ulcer
to heal was associated with increased levels of various
inﬂammatory cytokines, including tumor necrosis factor
a (TNFa), G-CSF, GRO, MCP-1, and leptin, which are
known to be increased in diabetes and diabetes complica-
tions (11,12). It should be emphasized that these increased
inﬂammatory levels were observed in serum specimens
taken at the baseline visit, which occurred on average ~8
months before the development of foot ulceration. There-
fore, the observed raised levels cannot be attributed to
mechanisms that are related with the healing process of an
existing ulcer and clearly indicate that a pre-existing low-
grade proinﬂammatory state, which already has been rec-
ognized as a major factor of metabolic and cardiovascular
disease, has a negative impact of the healing of DFUs
(10,13). Of interest, the soluble IL-2 receptor serum level,
which increases considerably after acute trauma or burns
and correlates with immunosuppression, was reduced in
patents whose ulcers failed to heal (14).
The PDGF-AA and FGF-2 levels were higher in diabetic
patients whose ulcers failed to heal compared with those
whose did, whereas the EGF, TGFa, and VEGF levels tended
to be higher but failed to reach statistical signiﬁcance. Fur-
thermore, patients whose ulcers failed to had growth factor
levels closer to those observed in patients with active foot
TABLE 4
Results of growth factors and cytokines in diabetic patients with and without foot ulceration
Diabetic patients
with no ulcers
Diabetic patients
with ulcers P
Healed
ulcers
Nonhealed
ulcers P
n 74 30 16 14
PDGF-AA (ng/mL) 17.5 (11.3–31.2) 19.4 (10.3–27.9) NS 13.2 (9.2–22.5) 25.6 (15.7–30.0) ,0.05
EGF (pg/mL) 45.6 (31.9–59.88) 35.1 (15.2–49.0) ,0.02 24.6 (11.2–42.3) 35.4 (22.4–59.2) NS
FGF-2 (pg/mL) 39.5 (28.3–54.6) 32.5 (24.6–43.2) ,0.05 26.4 (21.4–32.1) 39.4 (36.0–48.1) ,0.01
TGFa (pg/mL) 14.9 (9.9–30.6) 11.0 (6.2–20.9) NS 6.34 (3.0–15.8) 11.3 (10.2–26.2) NS
VEGF (pg/mL) 172 (66–370) 120 (62–218) NS 116 (50–157) 122 (67–303) NS
Leptin (ng/mL) 18.7 (8.2–32.4) 16.0 (6.9–25.2) NS 9.7 (3.3–21.9) 19.8 (14.4–36.0) ,0.05
G-CSF (pg/mL) 20.1 (13.6–29.7) 19.4 (13.8–24.4) NS 15.2 (9.4–21.9) 23.4 (16.0–27.7) ,0.02
GRO (ng/mL) 1.4 (0.9–1.8) 1.1 (0.9–1.4) NS 1.0 (0.8–1.3) 1.2 (1.1–2.0) ,0.05
IL-6 (pg/mL) 16.0 (9.7–44.0) 12.6 (8.8–20.4) = 0.052 12.5 (5.1–14.6) 14.9 (8.9–27.5) NS
IL-8 (pg/mL) 18.5 (12.3–45.9) 14.3 (9.6–31.3) NS 19.7 (7.9–31.7) 12.0 (10.2–26.9) NS
INF-g (pg/mL) 11.2 (3.7–20.5) 5.7 (2.0–12.4) ,0.05 3.3 (1.5–10.1) 6.3 (3.9–29.6) NS
MCP-1 (pg/mL) 503 (351–686) 563 (402–687) NS 437 (276–553) 628 (587–895) ,0.01
MIP-1a (pg/mL) 55.3 (40.6–77.4) 41.3 (32.5–57.8) ,0.05 37.9 (26.5–57) 45.9 (38.5–67.7) NS
MIP-1b (pg/mL) 65.2 (37.2–101) 44.1 (35.2–64.4) ,0.05 37.8 (33.1–47.6) 59.3 (41.7–67.4) NS
IL-2 receptor serum
(pg/mL) 66 (31–99) 83 (50–105) NS 98 (57–130) 62 (23–83) ,0.05
MMP-9 (ng/mL) 201 (140–321) 230 (139–376) NS 203 (118–275) 321 (174–508) ,0.02
tPAI-1 (ng/mL) 52 (38–72) 46 (38–77) NS 44 (36–51) 72 (47–88) ,0.05
TNFa (pg/mL) 6.80 (5.45–8.66) 6.41 (4.91–9.42) NS 5.43 (4.24–7.95) 8.77 (6.23–11.75) ,0.01
High-sensitivity C-reactive
protein (mg/mL) 11.3 (2.8–46.0) 11.6 (5.4–37.8) NS 8.2 (4.4–20.5) 15.1 (5.6–67.5) NS
Data are medians (ﬁrst to third quartiles). NS, not signiﬁcant.
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2942 DIABETES, VOL. 61, NOVEMBER 2012 diabetes.diabetesjournals.orgFIG. 2. Differences in serum TNFa, MCP-1, MMP-9, and FGF-2 among diabetic patients who did not develop DFUs, those who developed foot
ulceration and completely healed over a 12-week period (Healers), and those who developed foot ulceration and failed to heal over the same time
period (Nonhealers).
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lower levels. These observations indicate a possible resis-
tance to growth factor action. Glycation of various growth
factors, along with increased MMP-9 and PTPB1 expression
that were examined in this study, also may contribute to this
resistance to growth factor function (15). This resistance
may be one of the main reasons responsible for the failure of
most clinical trials that have studied the effects of growth
factors for DFU treatment (16).
MMP-9 is mainly released by inﬂammatory cells and is
involved in the breaking down of matrix proteins and
growth factors (17). Increased MMP-9 levels are present in
various chronic nonhealing wounds, including DFUs (18). In
the current study, increased serum levels long before the
development of DFUs are associated with failure of an ulcer
to heal. Of interest, patients with nonhealing ulcers also had
higher levels of tPA, which is known to upregulate the ex-
pression of MMP-9 (19).
As all the above-mentioned changes were systemic, we
also used forearm-skin biopsies in the same participants
and at the same time points to focus on tissue-speciﬁc
changes. Our results indicate that diabetic patients had
higher dermis inﬁltration by inﬂammatory cells, a sign of
chronic inﬂammation, which is compatible with the well-
known diabetes generalized proinﬂammatory status. MMP-9
expression by inﬂammatory stromal cells also was higher in
the diabetic patients, suggesting that these cells may be
a source for the observed increased systemic levels in the
same population. To the best of our knowledge, this is the
ﬁrst time that such skin changes are reported in diabetic
patients.
Given the high levels of growth factors in patients whose
ulcers failed to heal, indicating a resistance to their action,
we explored possible mechanisms that could be related to
this, and we focused on the role of PTP1B. PTP1B is
a ubiquitously expressed protein tyrosine phosphatase that
localizes in the endoplasmic reticulum, is upregulated by
inﬂammation, and negatively regulates the signaling of in-
sulin, leptin, and various growth factors that are involved in
wound healing, such as VEGF, EGF, PDGF, and TGFb (20).
Ongoing animal studies in our unit indicate that both diabetic
and nondiabetic PTP1B knockout mice have enhanced
wound healing, increased healing response to topical leptin
application, and increased periwound oxygen saturation
(21). In humans, PTP1B overexpression and increased ac-
tivity has been reported in the adipose tissue, especially
the omental tissue (22,23). This is the ﬁrst study to report
increased expression in all prominent skin cell popula-
tions of diabetic patients, whereas patients whose ulcers
failed to heal had marginally increased expression in the
endothelial cells when compared with patients whose
ulcers healed.
Taken in context, our results indicate that there is in-
creased extracellular MMP-9 and intracellular PTP1B ex-
pression, leading to local inactivation and resistance to the
action of various growth factors that are involved in wound
healing. Furthermore, this leads to increased levels of
circulating growth factors in a way that is similar to the
increased insulin levels in situations of insulin resis-
tance. Therefore, in case this hypothesis is correct, local
wound inhibition of MMP-9 and/or PTP1B may have the
potential to reverse these conditions and lead to promote
wound healing of DFUs. Of note, PTP1B inhibitors al-
ready have been developed and currently are under
consideration as a possible treatment of type 2 diabetes
and may prove candidates for local treatment of DFUs
(24,25).
The number of dermis vessels that were observed during
the hematoxylin and eosin analysis was higher in the
patients whose ulcers healed. Furthermore, CD31 staining
showed a higher number of endothelial cells proliferating
around preexisting vessels and blood vessels in diabetic
TABLE 5
Results of the forearm-skin biopsy analysis
Control subjects Diabetic patients P
n 12 71
Age (years) 56 6 86 0 6 6N S
Males (%) 4 (33) 48 (68) ,0.05
Hematoxylin and eosin
Total number of cells per biopsy 83 6 44 114 6 43 ,0.05
Perivascular inﬂammatory cells 14 6 10 8 6 7 ,0.05
Number of vessels in the dermis 6 6 37 6 2N S
Factor XIIIa expression 1.5 6 0.5 1.9 6 0.8 ,0.05
Factor XIIIa intensity of staining 1.1 6 0.3 1.7 6 0.7 ,0.001
CD45-expressing cells around skin vessels 8 6 71 5 6 11 ,0.02
CD31-proliferating cells around skin vessels 0 6 01 6 1 ,0.02
CD31-expressing interstitial cells 0.82 6 0.98 1.75 6 1.74 ,0.02
Number of blood vessels 21 6 92 7 6 11 ,0.05
Number of inﬂammatory stromal cells expressing MMP-9 1.3 6 0.7 2.0 6 0.7 ,0.001
Number of epidermal basal cells expressing PTP1B 1.2 6 0.4 2.0 6 0.8 ,0.01
Number of endothelial cells expressing PTP1B 1.1 6 0.3 1.9 6 0.6 ,0.0001
Number of ﬁbroblasts and/or ﬁbrocytes expressing PTP1B 1.1 6 0.3 2.1 6 0.9 ,0.001
Number of inﬂammatory cells expressing PTP1B 1.1 6 0.3 2.0 6 0.9 ,0.001
PTP1B intensity of staining in all cells 1.2 6 0.4 2.3 6 0.7 ,0.0001
Number of epidermal basal cells expressing VEGF 2.3 6 0.6 2.2 6 0.7 NS
Number of endothelial cells expressing VEGF 1.5 6 0.7 1.3 6 0.6 NS
Number of ﬁbroblasts and/or ﬁbrocytes expressing VEGF 1.9 6 0.5 1.7 6 0.7 NS
Number of inﬂammatory cells expressing VEGF 1.1 6 0.3 1.1 6 0.3 NS
VEGF intensity of staining in all cells 2.5 6 0.5 2.4 6 0.7 NS
Data are means 6 SD. NS, not signiﬁcant.
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2944 DIABETES, VOL. 61, NOVEMBER 2012 diabetes.diabetesjournals.orgFIG. 3. Forearm-skin biopsy immunohistochemistry analysis (frozen sections, 3100 magniﬁcation). A: Hematoxylin and eosin staining in a skin
biopsy from a diabetic patient showing round cell inﬂammatory reaction around blood vessels (black arrows), round inﬂammatory cells in dermis
far from vessels (red arrow), and ﬁbrocytes/ﬁbroblast (green arrows). B: Hematoxylin and eosin staining in a healthy control subject shows
superﬁcial blood vessels without perivascular round cell inﬁltration (black arrows). In the dermis, there are normal collagen bundles, without
excess numbers of ﬁbrocytes/ﬁbroblasts or round single cells. C: CD45RO staining in a diabetic patient showing numerous positive lymphoid cells
(round cells) around blood vessels (black arrows). D: CD45RO staining in a healthy subject showing a few positive lymphoid cells (round cells)
around blood vessels (black arrows). E: MMP-9 staining in a diabetic patient showing intense expression by stromal cells (green arrows). In
addition, the antibody was expressed by endothelial cells (black arrows) and reveals the basement membrane of blood vessels (red arrows).
F: MMP-9 staining in a healthy control subject. There is faint expression by stromal cells (green arrows) and limited expression by endothelial
cells (black arrows). G: PTP1B staining in a diabetic patient showing cytoplasmic, membranous, or paranuclear dot-like staining pattern. PTP1B is
strongly expressed by endothelial cells (black arrows), inﬂammatory cells (red arrow), epidermal basal cells (brown arrow), and dermis cells,
mainly ﬁbroblast (blue arrow). H: PTP1B staining in a healthy control subject showing a faint stain pattern in ﬁbrocytes/ﬁbroblasts (black arrows)
and endothelial cells (green arrow). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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levels and skin immunohistochemistry studies, whereas
Western blot analysis showed higher foot-skin expression
in diabetic patients when compared with control subjects.
Previous studies in our unit and elsewhere have reported
an increase in serum VEGF in obese subjects and have
hypothesized that this promotes revascularization in the
adipose tissue that allows fat mass expansion (26,27).
The results of the current study suggest that a similar
increased vascularization exists at the skin level in di-
abetes, and its magnitude can affect complete wound
healing. Furthermore, these results are in contrast with
animal studies that have shown reduced VEGF expression
and neovascularization, raising questions regarding the
applicability of the existing animal models to the human
condition (28).
Ulcer healing is heavily inﬂuenced by the quality of the
provided care and the adherence to it by the patients. In
the current study, all patients were followed at our unit
by the same physicians who provided state-of-the-art
care, including education and appropriate ulcer off loading,
and also monitored the adherence to it (4). Because the
provided care was the same in all participants, we do
not believe that it had any inﬂuence in the observed
results.
A large number of the participants returned for a second
visit after a 20-month period. Because there were no major
differences in both serum and skin biopsy measurements
between these two visits, the data clearly indicate that the
observed changes are chronic ones that develop over long
periods of diabetes.
One limitation of the current study is that the skin bi-
opsies were taken from the forearm and not the foot of the
participating subjects. This was conducted because biopsies
on the dorsum of the foot would carry an unacceptable high
risk for complications, especially in the high-risk group.
Furthermore, given the considerable variety of cells that are
present in the skin and that play a role in wound healing, we
based our main analysis on immunohistochemistry because
it allows the study of each cell type separately. However, in
order to address the possible above limitations, we also
studied foot specimens from a different group of diabetic
patients and the results were very similar to the ones ob-
served at the forearm level, both when immunohistochem-
istry and Western blot analysis were used. Therefore, we
feel very conﬁdent that the observed results at the forearm
level indicate systemic skin changes and are representative
to changes at the foot level.
In summary, in this cohort prospective study we have shown
that systemic factors that are associated with foot ulceration
and impaired wound healing are present long before the de-
velopment of DFUs. Increased inﬂammation and skin expres-
sion of MMP-9, PTP1B, and serum growth factors were the
main factors associated with failure to heal DFUs. Targeting
these factors may prove helpful in the management of DFUs.
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